Skip to main content

Opioid Bellwether Trial Delayed by Federal Judge

Opioid Bellwether Trial Delayed by Federal Judge

Opioid Bellwether Trial Delayed by Federal Judge

Introduction

According to a recent order issued by U.S. District Judge Dan Polster, claims filed by four Northeast Ohio governments against opioid makers have been pushed back until October 21, this year.

The trial for the lawsuits filed by the cities of  Cleveland, Akron, Cuyahoga, and Summit counties was initially set to begin on March 18 and later moved to September 3. The judge also postponed the deadlines to complete expert reports and motions before the trial. Attorneys for the governments and the drug companies sought to delay the trial asserting in their filing that the discovery was ongoing despite exhaustion. Drug manufacturers and distributors such as Purdue Pharma and Ohio-based Cardinal Health are blamed in the opioid lawsuits, which claim that the companies were aware of the opioid addiction since a long time, yet failed to take suitable measures to prevent an epidemic. The Ohio cases are the first to go for trial among a series of bellwether trials lined up this year.

Opioid overdose has been the major reason for drug overdose deaths in the U.S., with 72,000 deaths reported last November. Opioid lawsuits are consolidated into a multidistrict litigation MDL No. 2804 (In Re: National Prescription Opiate Litigation) overlooked by Judge Polster in the Northern District of Ohio.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Attorneys Seek Reconsideration of Talc MDL Daubert Ruling

Categories: General

Plaintiffs’ attorneys are urging the U.S. District Judge overseeing the talcum powder lawsuit MDL to reconsider a recent decision for a second round…

Philips resolves DreamStation suits for $1.1B

Categories: Settlements

Dutch medical technology company Philips has finalized a $1.1 billion settlement in the United States to address lawsuits concerning faulty…

FDA OKs Generic OTC Naloxone Spray Approved by FDA

Categories: FDA Related

The FDA has granted approval for Amneal Pharmaceuticals to release a generic 4 mg naloxone hydrochloride nasal spray for over-the-counter (OTC) use, an announcement made in a press release.

Our Legal Drafting Services    
start @ $25 per hour.